Atovaquone-proguanil treatment failure in Plasmodium falciparum;Échec du traitement de Plasmodium falciparum par atovaquone-proguanil

Presse Medicale

Volumn 40, Issue 11, 2011, Pages 1081-1083

  Contentin, Laetitia ^a,b   Grammatico Guillon, Leslie ^a,b   Desoubeaux, Guillaume ^a,b   Baron, Sabine ^a,b   Thanh, Hai Duong ^a,b  

^a CHU BRETONNEAU   (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE PLUS PROGUANIL;

HUMAN; LETTER; MALARIA FALCIPARUM; TREATMENT FAILURE;

ADULT; ANTIMALARIALS; ATOVAQUONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EMIGRANTS AND IMMIGRANTS; FRANCE; GUINEA; HUMANS; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; PROGUANIL; QUININE; RECURRENCE; TRAVEL; TREATMENT FAILURE;

EID: 80755132268     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2011.03.009     Document Type: Letter

References (13)

1. Institut national de veille sanitaire. CNR Paludisme rapport d'activités année 2009.
2. Bruneel F, Tubach F, Corne P, Megarbane B, Mira J, Peytel E, et al. Severe imported Falciparum malaria: a cohort study in 400 critically ill adults. PLoS One;5.(10).
3. World Health Organization. World malaria report 2009.
4. Dunbar-Jacob J., Mortimer-Stephens M.K. Treatment adherence in chronic disease. J Clin Epidemiol 2001, 54(Suppl 1):S57-60.
5. Boggild A.K., Parise M.E., Lewis L.S., Kain K.C. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). Am J Trop Med Hyg 2007, 76(2):208-223.
6. Rolan P.E., Mercer A.J., Weatherley B.C., Holdich T., Meire H., Peck R.W., et al. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol 1994, 37(1):13-20.
7. Gallien S., Taieb F., Schlemmer F., Lagrange-Xelot M., Atlan A., Sarfati C., et al. Failure of atovaquone/proguanil to prevent Plasmodium ovale malaria in traveler returning from Cameroon. Travel Med Infect Dis 2008, 6(3):128-129.
8. Savini H., Bogreau H., Bertaux L., Bouchiba H., Kraemer P., Parzy D., et al. First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros. Antimicrob Agents Chemother 2008, 52(6):2283-2284.
9. Rose G.W., Suh K.N., Kain K.C., Le Saux N., McCarthy A.E. Atovaquone-proguanil resistance in imported falciparum malaria in a young child. Pediatr Infect Dis J 2008, 27(6):567-569.
10. Forestier E., Labe A., Raffenot D., Lecomte C., Rogeaux O. Post-malaria neurological syndrome complicating a relapse of Plasmodium falciparum malaria after atovaquone-proguanil treatment. Med Mal Infect 2011, 41(1):41-43.
11. Hyde J.E. Drug-resistant malaria. Trends Parasitol 2005, 21(11):494-498.
12. Sutherland C.J., Laundy M., Price N., Burke M., Fivelman Q.L., Pasvol G., et al. Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil. Malar J 2008, 7:240.
13. Thapar M.M., Gil J.P., Björkman A. In vitro recrudescence of Plasmodium falciparum parasites suppressed to dormant state by atovaquone alone and in combination with proguanil. Trans R Soc Trop Med Hyg 2005, 99(1):62-70.